ClinicalTrials.gg
CompletedNCT02767310Updated Jul 6, 2016

Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)

A Phase 1 interventional study of Rosuvastatin 20 mg film-coated tablets and Crestor 20 mg film-coated tablets in Healthy, sponsored by Verisfield UK Ltd. Greek Branch. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-06.

Sponsored by Verisfield UK Ltd. Greek Branch · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20 mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.

Read the detailed description

This study aims to compare the absorption and disposition kinetics of two products containing rosuvastatin under fasting conditions. These products are: Rosuvastatin/ Verisfield 20 mg film-coated tablets, a Test product manufactured by HELP S.A., Greece and Crestor™/ AstraZeneca 20 mg film-coated tablets, a Reference product manufactured by AstraZeneca, UK. The bioequivalence of a single 20 mg dose of both products will be assessed by comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles for rosuvastatin.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • two rosuvastatin-containing products
03

In context

Lead sponsor

Verisfield UK Ltd. Greek Branch is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide to participate in the study.
  • Comprehension of the nature and purpose of the study and willingness to comply with the requirements of the entire procedure.
  • Healthy adult, human Indian volunteers within the age range of 18 to 45 years (both inclusive).
  • (BMI) ≥ 18.50 kg/m2 to ≤ 30.00 kg/m2.
  • : ≥12.0 gm% for male and ≥11.5 gm% for female.
  • Absence of disease markers of I \& II, , HCVAb and P24 antigen test.
  • Females of childbearing age must be practicing an acceptable form of for at least six months before screening, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy.
  • Females of childbearing age agree to use acceptable form of birth control during the study and until the drug is washed out from the body, i.e. at least 14 days after last dosing, unless they have had bilateral oophorectomy or tubal ligation or their male partner has had vasectomy.
  • Absence of significant disease or abnormal laboratory values during the laboratory evaluations.
  • Absence of any diseases in medical history or physical examination during the screening.
  • Have a normal 12-lead or one with abnormality considered clinically insignificant.
  • Have a normal chest X-ray (P. A. view).
  • Non smokers (since last six months)
  • Negative serum β-HCG at the time of screening (for females only)

Exclusion criteria

Exclusion Criteria:

  • History / evidence of allergy or to rosuvastatin or to any of the or to any other drug.
  • Any major illness within the last three months or any significant ongoing chronic medical illness.
  • History of or active liver or kidney disease.
  • History of or active deep vein thrombosis and thromboembolic disorders.
  • History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia, endometriosis and undiagnosed vaginal bleeding (for females only).
  • History of drug abuse (including barbiturates, benzodiazepines, opioids, cocaine, cannabinoids and amphetamine etc.) within the last three months.
  • History of neuropsychiatric diseases.
  • History of hypothyroidism.
  • Personal or family history of hereditary muscular disorders.
  • History of myopathy.
  • History of myalgia.
  • History of rhabdomyolysis.
  • History of alcohol abuse.
  • History of proteinuria.
  • Asian population (except Indian).
  • History of interstitial lung disease.
  • History of or current gastro-intestinal diseases influencing drug absorption.
  • History of alcoholism (more than two years), moderate drinkers (more than three drinks per day).
  • Participation in any clinical trial within last three months.
  • History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
  • Donation of blood (one unit or 350 mL or more) within last three months.
  • Use of any prescription drug therapy within last two weeks and over the counter (OTC) drugs or herbal products within last one week.
  • Pregnant women.
  • Breast feeding women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Test Product

    Rosuvastatin 20 mg film-coated tablets

    Drug: Rosuvastatin 20 mg film-coated tablets

  • Active comparator
    Reference product

    Crestor 20 mg film-coated tablets

    Drug: Crestor 20 mg film-coated tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration (AUC0-t) from zero (0) hours to time (t)

    The area under the plasma concentration versus time curve, from time zero (0) to t hours

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

  2. Maximum concentration (Cmax)

    Maximum measured plasma concentration

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

Secondary outcomes

  1. Time to maximum concentration (Tmax)

    Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

  2. Elimination rate constant (Kel)

    Apparent first-order elimination or terminal rate constant

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

  3. Terminal half life (t1/2)

    The elimination or terminal half-life

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

  4. Area under the plasma concentration (AUC0-infinity) from zero (0) hours to infinity

    The area under the plasma concentration versus time curve from time (0) to infinity

    Time frame: Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose

  5. Number of participants with Adverse Events

    Time frame: 6 days

07

Study locations

1 site
  • Synchron Research Services Pvt. Ltd.
    Ahmedabad, Gujarat 380056, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2016
First posted
May 10, 2016
Start
May 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jul 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02767310
Lead sponsor
Verisfield UK Ltd. Greek Branch
Responsible party
Sponsor
First posted
May 10, 2016
Start date
May 2016
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jul 6, 2016

Study contacts

Kathiria Jayesh, M.D.
principal investigator · Synchron Research Services Pvt. Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion